Literature DB >> 26017856

FHL1 inhibits the growth of tongue squamous cell carcinoma cells via G1/S cell cycle arrest.

Wei Ren1, Panfeng Lian1, Long Cheng2, Peiyun Du2, Xin Guan2, Hongyuan Wang2, Lihua Ding2, Zhenyang Gao3, Xin Huang4, Fengjun Xiao5, Lisheng Wang5, Xiaolin Bi6, Qinong Ye2, Enqun Wang1.   

Abstract

Four and a half LIM protein 1 (FHL1) has been characterized as a tumor suppressor in various types of tumor. However, the biological function and underlying mechanism of FHL1 in tongue squamous cell carcinoma (TSCC) remain to be elucidated. The present study demonstrated that FHL1 inhibits anchorage‑dependent and ‑independent growth of TSCC cells in vitro and tumor growth in nude mice, as determined by cell proliferation and soft agar assays. Knockdown of FHL1 with FHL1 small interfering RNA (siRNA) promoted tumor growth in nude mice. Mechanistically, flow cytometric analysis showed that knockdown of FHL1 promoted G1/S cell cycle progression. Furthermore, expression of cell cycle‑associated regulators, cyclin D and cyclin E, were detected by western blotting and reverse transcription‑quantitative polymerase chain reaction. Cyclin D and cyclin E were markedly elevated at both the protein and mRNA level in the FHL1 siRNA‑transfected cells. These results suggested that FHL1 has a tumor suppressive role in TSCC and that FHL1 may be a useful target for TSCC gene therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26017856     DOI: 10.3892/mmr.2015.3844

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.

Authors:  Qiankun Luo; Yanfeng Pan; Qiang Fu; Xu Zhang; Shuai Zhou; Pengfei Yu; Huiyuan Tian; Pan Liu; Song Chen; Hongwei Zhang; Tao Qin
Journal:  Cell Biol Toxicol       Date:  2022-02-10       Impact factor: 6.691

2.  MiR-183-5p Promotes Proliferation, Metastasis and Angiogenesis in Breast Cancer Cells through Negatively Regulating Four and a Half LIM Protein 1.

Authors:  Yi Li; Qing'an Zeng; Jiliang Qiu; Ting Pang; Fenglian Ye; Lin Huang; Xuexia Zhang
Journal:  J Breast Cancer       Date:  2020-08-25       Impact factor: 3.588

3.  Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.

Authors:  Dong-Dong Cheng; Hui-Zhen Zhang; Jun-Qing Yuan; Shi-Jie Li; Qing-Cheng Yang; Cun-Yi Fan
Journal:  Oncotarget       Date:  2017-04-18

4.  CD63 inhibits the cell migration and invasion ability of tongue squamous cell carcinoma.

Authors:  Wen-Hui Liu; Xin Li; Xin-Ling Zhu; Mei-Ling Hou; Wei Zhao
Journal:  Oncol Lett       Date:  2018-04-16       Impact factor: 2.967

Review 5.  Four and a half LIM domains protein 1 can be as a double-edged sword in cancer progression.

Authors:  Xiaofan Wei; Hongquan Zhang
Journal:  Cancer Biol Med       Date:  2020-05-15       Impact factor: 4.248

6.  FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors.

Authors:  Pengping Li; Guodong Cao; Yuefeng Zhang; Jingbo Shi; Kailun Cai; Lei Zhen; Xiaobo He; Yizhao Zhou; Yongzhou Li; Yi Zhu; Maoming Xiong; Yulian Wu
Journal:  Aging (Albany NY)       Date:  2020-01-13       Impact factor: 5.682

7.  MiR-96-5p Facilitates Lung Adenocarcinoma Cell Phenotypes by Inhibiting FHL1.

Authors:  Feng Zhou; Chaojie Qian; Tingting Chen; Xiaoliang Zang
Journal:  Comput Math Methods Med       Date:  2022-08-16       Impact factor: 2.809

8.  A Liquid Chromatography with Tandem Mass Spectrometry-Based Proteomic Analysis of Cells Cultured in DMEM 10% FBS and Chemically Defined Medium Using Human Adipose-Derived Mesenchymal Stem Cells.

Authors:  Yoshiki Nakashima; Saifun Nahar; Chika Miyagi-Shiohira; Takao Kinjo; Naoya Kobayashi; Issei Saitoh; Masami Watanabe; Jiro Fujita; Hirofumi Noguchi
Journal:  Int J Mol Sci       Date:  2018-07-13       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.